Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
New Leaf Venture Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
New Leaf Venture Partners

New Leaf Venture Partners

Operating

New Leaf Venture Partners, a NY-based VC firm, invests in biopharma, IT, medical devices, and bio-research.

Location
New York City, NY, US
Founded
2005
Firm
Compare
Portfolio
Employees
Website

Investments

Arvist
Arvist

Total Raised

$1.1M

Rounds

2

Pre-Seed$1MSeptember 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Series Unknown$100MFebruary 2022
Arine
Arine

Total Raised

$40M

Rounds

5

Series B$29MAugust 2022
Electra Therapeutics
Electra Therapeutics

Total Raised

$100M

Rounds

2

Series B$84MFebruary 2022
Asimily
Asimily

Total Raised

$20M

Rounds

4

Series Unknown$10MNovember 2021
Cleerly
Cleerly

Total Raised

$280.5M

Rounds

3

Series B$43MJune 2021
BrightInsight
BrightInsight

Total Raised

$166M

Rounds

3

Series C$101MMarch 2021
Series B$40MJune 2020
Series A$25MSeptember 2019
TigerConnect
TigerConnect

Total Raised

$448.9M

Rounds

8

Series D$45MOctober 2020
AiCure
AiCure

Total Raised

$68.8M

Rounds

6

Series C$24.5MNovember 2019
Series B$15MNovember 2017
Qlaris Bio
Qlaris Bio

Total Raised

$25M

Rounds

1

Series A$25MAugust 2019
CuraSen Therapeutics
CuraSen Therapeutics

Total Raised

$95.9M

Rounds

5

Series A$54.5MOctober 2018
Alector
Alector
Public

Total Raised

$269.5M

Rounds

7

Series E$133MJuly 2018
Neurana Pharmaceuticals
Neurana Pharmaceuticals

Total Raised

$60M

Rounds

1

Series A$60MMay 2018
Kyruus
Kyruus

Total Raised

$183.3M

Rounds

12

Corporate Round$10MApril 2018
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Series C$55MApril 2018
Braeburn
Braeburn

Total Raised

$133M

Rounds

2

Debt Financing$110MJanuary 2018
Aptinyx
Aptinyx
Public

Total Raised

$273.9M

Rounds

7

Series B$70MDecember 2017
Series A$65MMay 2016
Truveris
Truveris

Total Raised

$54M

Rounds

5

Series D$25MSeptember 2017
Neuronetics
Neuronetics
Public

Total Raised

$373.4M

Rounds

13

Series G$15MJune 2017
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Acquired

Total Raised

$1B

Rounds

8

Series C$52MJune 2017